PEPG
Live chart
What they do
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1.
For information only · Important disclosures
Grades vs sector
No sector grades for PEPG yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.
Our models
Not held by any of our 5 live models right now.
News
More newsKey stats
Valuation and fundamentals
Valuation & fundamentals
Earnings
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-08-06 | -0.29 | -0.26 | +9.9% |
| 2026-03-04 | -0.39 | -0.27 | +31.5% |
| 2025-11-12 | -0.56 | -0.52 | +8.0% |
| 2025-08-07 | -0.85 | -0.70 | +17.3% |
| 2025-05-08 | -0.75 | -0.92 | -22.7% |
| 2025-02-24 | -0.72 | -0.68 | +5.6% |
| 2024-11-07 | -0.77 | -0.66 | +14.3% |
| 2024-08-08 | -0.68 | -0.87 | -27.0% |
Stats refreshed 2026-10-21 18:00:39 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
Independent research · Not investment advice · Important disclosures · Contact desk@coteau.app
Coteau Systematic Strategies publishes stock research and model portfolios. Results are hypothetical unless marked Live. Data: Yahoo Finance (15-min delayed), SEC EDGAR and the House Clerk.
Beta 0.9 · Oct 21, 2026